Patents Assigned to Leadiant Biosciences SA
  • Roneparstat combined therapy of multiple myeloma
    Patent number: 10576101
    Abstract: The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib or with melphalan improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 3, 2020
    Assignees: Leadiant Biosciences SA, The UAB Research Foundation
    Inventors: Ralph D. Sanderson, Vishnu Prakash C. Ramani, Alessandro Noseda, Paola Barbieri